FURX Insider Trading Activity and SEC Form 4 Filings
FURX insider trading summary
No open-market insider purchases or sales of Furiex Pharmaceuticals, Inc. (FURX) have been reported on SEC Form 4 in the past 12 months.
Latest FURX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jul 2, 2014 | Actavis plc | 10% Owner | Buy | $1.06B (11,169,066 @ $95.00) |
| Jul 2, 2014 | Forest Laboratories, LLC | 10% Owner | Buy | $1.06B (11,169,066 @ $95.00) |
| Jun 24, 2014 | Sailash Patel | Chief Financial Officer | Sell | $3.4M (32,928 @ $104.00) |
| Jun 24, 2014 | Paul S Covington | Senior VP-Clinical Operations | Sell | $1.1M (10,368 @ $104.12) |
| Jun 18, 2014 | Paul S Covington | Senior VP-Clinical Operations | Sell | $4.8M (45,691 @ $104.11) |
| Jun 17, 2014 | Gail Frances McIntyre | Senior Vice President-Research | Sell | $841K (8,008 @ $105.00) |
| Jun 16, 2014 | Gail Frances McIntyre | Senior Vice President-Research | Sell | $2.7M (26,000 @ $105.01) |
| Jun 16, 2014 | Gail Frances McIntyre | Senior Vice President-Research | Sell | $3.5M (32,928 @ $105.00) |
| Jun 16, 2014 | Gail Frances McIntyre | Senior Vice President-Research | Sell | $390K (3,717 @ $105.05) |
| Jun 16, 2014 | Gail Frances McIntyre | Senior Vice President-Research | Sell | $399K (3,804 @ $105.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.